Thu 8/17/2017 05:54 ET
DJIA22024.8725.880.12%SOLAR21.740.190.87%GOLD1288.308.630.67%Shanghai3136.7734.501.10%
S&P 5002468.113.460.14%BANKS25.040.050.20%OIL46.800.741.58%Nikkei19702.6327.580.14%
NASDAQ6345.1112.120.19%SEMI87.350.180.21%US/EU1.180.000.27%Futures2464.253.250.13%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - QualityStocks    QualityStocks.net

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  
From: madrid (Rep: 0)Date: 04/30/2017 10:25
Forum: QualityStocks - Msg #10710Thread #673924253 (Rec: 0)
Bayer AG


First quarter of 2017
Strong start to the year for Bayer

Group sales increase to €13.2 billion (Fx & portfolio adj.: +9.4%)
EBITDA before special items raised to €3.9 billion (+14.9%)
Growth momentum across all segments
Very good business development at Pharmaceuticals
Significant increase in sales and earnings at Covestro
Net income €2.1 billion (+37.9%)
Core earnings per share €2.62 (+11.5%)
Group outlook for 2017 raised, driven by Covestro performance
Economic situation of the Bayer Group

The Bayer Group got off to a very successful start to 2017. In the first quarter, sales increased by 9.4% on a currency- and portfolio-adjusted basis (Fx & portfolio adj.) to €13.2 billion and EBITDA before special items by a substantial 14.9% to €3.9 billion. At Pharmaceuticals, we once again benefited from the very good performance of our key growth products. Consumer Health, Crop Science and Animal Health also registered increases in sales and EBITDA before special items. Covestro posted substantial growth in sales and earnings.





http://www.quarterly-report-2017-q1.bayer.com/

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser madrid: Reward | Watch | Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.